Effects of exercise on vasomotor symptoms in menopausal women: a systematic review and meta-analysis

Liu, Ting; Chen, S.; Mielke, Grégore Iven; McCarthy, Alexandra; Bailey, Tom G.

doi:10.1080/13697137.2022.2097865

Cited by 16 publications

(14 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, we found no indication that physical activity would mitigate a potential detrimental effect of VMS on the coronary arteries. This somewhat contradicts previous results showing that physically active as compared to sedentary postmenopausal women report less VMS (20). Although the current study was not designed to study treatment effects, it is relevant to note that the association between >5 years of VMS and coronary atherosclerosis became stronger when adjusting for MHT, as this could possibly signal a mitigating effect.…”

Section: Discussioncontrasting

confidence: 93%

See 1 more Smart Citation

Menopausal vasomotor symptoms and subclinical atherosclerotic cardiovascular disease – a population-based study

Nilsson

Qvick

Henriksson

et al. 2023

Preprint

View full text Add to dashboard Cite

BACKGROUND Menopausal vasomotor symptoms (VMS) have been associated with subclinical and manifest atherosclerotic cardiovascular disease (ASCVD) but have not been studied in relation to image-detected coronary atherosclerosis. We assessed the association between VMS and subclinical ASCVD in peri- and postmenopausal women, considering a wide range of cardiovascular related risk factors that could potentially influence the relationship. METHODS This cross-sectional population-based study was conducted on a subset of participants from the Swedish CArdioPulmonary BioImage Study (SCAPIS), including women 50-65 years of age. The women underwent comprehensive cardiovascular assessments and completed an extensive questionnaire, which included questions about current and previous menopause-related symptoms. VMS was assessed on a 4-point scale and analyzed in relation to subclinical ASCVD, detected via coronary computed tomography angiography (CCTA), coronary artery calcium score (CACS) and carotid ultrasound using logistic regression analyses. RESULTS Of 2995 women included, 14.2% reported previous or on-going severe VMS (n=425), 18.1% moderate VMS (n=543), and 67.7% no or mild VMS (n=2027). Women who had ever experienced severe VMS, but not those with ever moderate VMS, had higher prevalence of CCTA-detected coronary atherosclerosis (34.1 vs 27.8%, p=0.017), but not segmental involvement score (SIS) >3 (4.5 vs 5.1%, p>0.05), CACS>100 (5.8 vs 6.6%, p>0.05) or any carotid plaque (47.6% vs 46.6%, p>0.05) than women with never or ever mild VMS. Using the same reference, ever severe but not moderate VMS was significantly associated with CCTA-detected coronary atherosclerosis, odds ratio (OR) after multivariable adjustment 1.33, 95% CI 1.02?1.72. This association was only present for durations of severe VMS of more than 5 years (multivariable adjusted OR 1.53 95% CI 1.09-2.14) or when the onset of severe VMS occurred before menopause (multivariable adjusted OR 1.60 95% CI 1.06-2.42). Additional adjustment for menopausal hormone therapy strengthened the associations whereas additional adjustment for physical activity did not. No significant association with SIS>3, CACS>100, nor with any carotid plaque was observed. CONCLUSIONS Previous or on-going severe but not moderate VMS were significantly associated with CCTA-detected coronary atherosclerosis, independent of a broad range of cardiovascular risk factors. No corresponding associations was observed for SIS>3, CACS>100 or carotid atherosclerosis.

show abstract

Section: Discussioncontrasting

confidence: 93%

“…Current guidelines support MHT for bothersome VMS in women within 10 years since menopause or ≤60 years of age at treatment initiation (19). Another proposed therapy for treatment of VMS is physical activity (20), but as the evidence is ambiguous it is not included in prevailing VMS treatment guidelines.…”

Section: Introductionmentioning

confidence: 99%

Menopausal vasomotor symptoms and subclinical atherosclerotic cardiovascular disease – a population-based study

Nilsson

Qvick

Henriksson

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…6 Exercise might also be effective in treating vasomotor symptoms, however more studies are needed on the topic. 33 For the woman presented in scenario 3, MHT can be considered.…”

Section: Scenario 3: Prescribing Mht To a Perimenopausal Woman With E...mentioning

confidence: 99%

“…Cognitive behavioral therapy, hypnotherapy, selected antidepressants (paroxetine, venlafaxine, escitalopram, citalopram) and gabapentin are some of the therapies shown to reduce vasomotor symptoms in menopausal women 6 . Exercise might also be effective in treating vasomotor symptoms, however more studies are needed on the topic 33 …”

Section: Clinical Scenariosmentioning

confidence: 99%

Endometriosis and menopause—management strategies based on clinical scenarios

Jakson

Hirschberg

Gidlöf

2023

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Endometriosis is largely considered a premenopausal disease with symptoms often improving during menopausal transition. However, 2%–4% of postmenopausal women are affected by endometriosis symptoms. At the same time, many peri‐ and postmenopausal women experience menopausal symptoms and inquire about treatment. Because of the estrogen‐dependent nature of endometriosis, treatment with menopausal hormone therapy requires careful assessment of the patient but should nevertheless be considered. Recurrence of endometriosis symptoms and risk for malignant transformation are potential risks to weigh when prescribing menopausal hormonal therapy. Choice of treatment should be guided by the presence and severity of current endometriosis symptoms, nature of menopausal symptoms, risk assessment of potential contraindications for treatment in patient history, and preferences of the woman after an informative discussion. Recurrence of endometriosis symptoms in a postmenopausal patient should always prompt rigorous evaluation, both in the presence and absence of hormonal treatment. Many recommendations on the topic are based on expert opinion and new studies are urgently needed to obtain evidence for optimal patient care.

show abstract

“…Exercise is an effective method for easily and noninvasively improving the quality of life in middle-aged women [1]. Postmenopausal symptoms, such as hot flushes, that occur due to the menopausal transition in women are also readily alleviated by a simple sports program [2][3][4]. However, various life circumstances might lead to longer breaks in women's exercise habits [5] Although a few studies [6][7][8] focus on detraining effects on muscle strength or bone mineral density after exercise periods in women, these did not include studies focusing on menopausal symptoms.…”

Section: Introductionmentioning

confidence: 99%

Impact of 3 months of detraining after high intensity exercise on menopause-related symptoms in early postmenopausal women – results of the randomized controlled actlife project

Jungmann

Hettchen²,

Kohl³

et al. 2023

Front. Sports Act. Living

View full text Add to dashboard Cite

Regular exercise might reduce postmenopausal symptoms, however even short-moderate periods of absence from exercise training might significantly reduce these positive effects. The aim of the study was thus to determine detraining effects on postmenopausal symptoms after a 3-month detraining period in early post-menopausal women. After 13 months, the exercise group (EG: n = 27; 54.6 ± 2.0; 23.6 ± 3.3 kg/m2) had to abruptly stop their supervised, facility-based, high intensity aerobic and resistance group exercise conducted three times per week due to the COVID-19 pandemic and the corresponding lockdown of all training facilities in Germany. In parallel, the control group (CG: n = 27; 55.6 ± 1.6 years, 25.2 ± 5.2 kg/m2) had to terminate their low-intensity exercise program performed once per week. Study endpoint as determined after 3 months of detraining was menopausal symptoms as determined by the Menopausal Rating Scale II (MRS II). The intention to treat principle with multiple imputation was applied. After 13 months of intense multicomponent exercise and significant exercise-induced effects on menopausal symptoms, a further 3 months of detraining resulted in non-significant deteriorations (p = .106) in the exercise group, while non-significant improvements were observed in the control group (p = .180). Corresponding group differences were significant (p = .036) after detraining. Of importance, self-reported individual outdoor activities increased by about 40% in both groups during the three-month lock-down period. Three months of absence from a supervised high-intensity group exercise protocol resulted in detraining effects on postmenopausal symptoms even when outdoor physical activity was increased significantly. Trial registration numberClinicalTrials.gov: NCT03959995

show abstract

Effects of exercise on vasomotor symptoms in menopausal women: a systematic review and meta-analysis

Cited by 16 publications

References 45 publications

Menopausal vasomotor symptoms and subclinical atherosclerotic cardiovascular disease – a population-based study

Menopausal vasomotor symptoms and subclinical atherosclerotic cardiovascular disease – a population-based study

Endometriosis and menopause—management strategies based on clinical scenarios

Impact of 3 months of detraining after high intensity exercise on menopause-related symptoms in early postmenopausal women – results of the randomized controlled actlife project

Contact Info

Product

Resources

About